Thrombosis and Hemostasis Issues in Cancer Patients with COVID-19

Horowitz, Netanel A.; Brenner, Benjamin

doi:10.1055/s-0040-1714275

Cited by 18 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Guidelines recommend low-molecularweight heparin (LMWH) anticoagulation in outpatients with risk of VTE outweighing the risk of bleeding,(157,158) or in hospitalized patients with COVID-19. Consensus guidelines recommend initiating standard prophylactic dosing in all hospitalized patients who do not have contraindications for use(159,160). Treatment of acute thrombosis in the context of COVID-19 and cancer should follow those of guidelines (161-163)(164).…”

mentioning

confidence: 99%

Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer

Elkrief¹,

Wu²,

Jani³

et al. 2021

Cancer Discov

View full text Add to dashboard Cite

The ongoing COVID-19 pandemic has left patients with current or past history of cancer facing disparate consequences at every stage of the cancer trajectory. This comprehensive review offers a landscape analysis of the current state of the literature on COVID-19 and cancer including the immune response to COVID-19, risk factors for severe disease, and impact of anticancer therapies. We also review the latest data on treatment of COVID-19 and vaccination safety and efficacy in patients with cancer, as well as impact of the pandemic on cancer care, including the urgent need for rapid evidence generation and realworld study designs.

show abstract

mentioning

confidence: 99%

Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer

Elkrief¹,

Wu²,

Jani³

et al. 2021

Cancer Discov

View full text Add to dashboard Cite

show abstract

“…Indeed, prothrombotic mechanisms differ in malignancy and COVID-19, and could, therefore, confer additional risk. The latest data about thrombosis and hemostasis issues in cancer patients with COVID-19 state that, as a rule, patients should receive pharmacological venous thromboembolism prophylaxis [ 12 ]. Prophylactic daily low-molecular-weight heparins (LMWHs) or twice daily subcutaneous unfractionated heparin (UFH) are recommended by the World Health Organisation [ 13 ].…”

Section: Discussionmentioning

confidence: 99%

Nonbacterial thrombotic endocarditis in a patient with gastric cancer and SARS-CoV-2 infection

Binet

Goffinet

Etogo-Asse

et al. 2021

Clin J Gastroenterol

View full text Add to dashboard Cite

Nonbacterial thrombotic endocarditis, formerly known as marantic endocarditis, is a very rare complication of advanced malignancy and other hypercoagulable states in which sterile, fibrin vegetations develop on heart valve leaflets. The most common malignancies associated with this entity are lung, pancreatic and gastric cancer. It has also been described as a presentation of COVID-19, which is known to be frequently complicated with coagulopathy and thromboembolic events. We report the case of a 62 year-old female patient newly diagnosed with stage IV gastric cancer and acute SARS-CoV-2 infection, presenting with confusion and homonymous hemianopsia in the setting of multiple acute ischemic strokes complicating a nonbacterial thrombotic mitral endocarditis. Herein, we discuss the underlying pathophysiology and make the hypothesis that SARS-CoV-2 infection could have participated in the pathogenesis of nonbacterial thrombotic endocarditis in our patient suffering from a gastric cancer.

show abstract

“…These suppositions raised from vast amounts of publications describing an immense presence of thrombosis recently observed in post mortem and during the severe cases SARS-CoV-2 in critical care and even those that already had received hospital discharge. (63,65,69,70) In this context, Biembengut and Souza Brasil (11) identified important coagulation modifiers among 80 compounds with Mpro inhibitor potential. The first was Argatroban; a direct thrombin inhibitor successfully used to treat HIT.…”

Section: Coagulation Modifiers Targeting Sars-cov-2 Main Proteasementioning

confidence: 97%

Should COVID-19 be branded to viral thrombotic fever?

Filho

Neto

Mengel

et al. 2021

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

Coronaviruses can cause a diverse array of clinical manifestations, from fever with symptoms of the common cold to highly lethal severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS). SARS-CoV-2, the coronavirus discovered in Hubei province, China, at the end of 2019, became known worldwide for causing coronavirus disease 2019 . Over one year's time period, the scientific community has produced a large bulk of knowledge about this disease and countless reports about its immune-pathological aspects. This knowledge, including data obtained in postmortem studies, points unequivocally to a hypercoagulability state. However, the name COVID-19 tells us very little about the true meaning of the disease. Our proposal is more comprehensive; it intends to frame COVID-19 in more clinical terminology, making an analogy to viral haemorrhagic fever (VHF). Thus, we found irrefutable evidence in the current literature that COVID-19 is the first viral disease that can be branded as a viral thrombotic fever. This manuscript points out that SARS-CoV-2 goes far beyond pneumonia or SARS. COVID-19 infections promote remarkable interactions among the endothelium, coagulation, and immune response, building up a background capable of promoting a "thrombotic storm," much more than a "cytokine storm." The importance of a viral protease called main protease (Mpro) is highlighted as a critical component for its replication in the host cell. A deeper analysis of this protease and its importance on the coagulation system is also discussed for the first time, mainly because of its similarity with the thrombin and factor Xa molecules, as recently pointed out by structural comparison crystallographic structures.

show abstract

Thrombosis and Hemostasis Issues in Cancer Patients with COVID-19

Cited by 18 publications

References 30 publications

Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer

Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer

Nonbacterial thrombotic endocarditis in a patient with gastric cancer and SARS-CoV-2 infection

Should COVID-19 be branded to viral thrombotic fever?

Contact Info

Product

Resources

About